Aarti Pharmalabs Share Price

Aarti Pharmachem Limited, formerly known as Aarti Organics Limited, was incorporated as a Public Limited Company in 2019. The Company changed the name from Aarti Organics Limited to Aarti Pharmachem Limited on July 1, 2021. The Company is engaged in manufacturer of Active Pharmaceutical Ingredients (API), Pharmaceutical Intermediates, New Chemical Entities (NCE), and Xanthine derivatives situated in India. It specialise in developing and manufacturing Highly Potent Active Pharmaceutical Ingredients (HPAPIs) critical for various therapeutic segments such as Anticancer, AntiAsthma, AntiHypertensive etc.In 2001, the Company commissioned first API manufacturing Unit in Dombivali (Unit 1) and started Xanthine Unit further it commissioned first API manufacturing Unit 4 in Tarapur for Regulated Markets in 2005 commissioned Caffeine production at Unit 5 with a capacity of 100 Metric Tonnes (MT) per month in 2016. It expanded block for CSD, Vapi and API, Tarapur units in 2022.The Scheme of Arrangement for the demerger of Pharma Business Undertaking from Aarti Industries Limited into its wholly owned subsidiary Aarti Pharmalabs Limited was effective on October 17, 2022 and operational from July 1, 2021. Pursuant to the said Demerger Scheme, Aarti Industries Limited hived off its Pharmaceutical Division into a separate entity Aarti Pharmalabs Limited and accordingly, all the assets and liabilities pertaining to the Pharma Business Undertaking got transferred and vested into the Company effective from the above said Date.Thereafter, the Company in 2023 commercialised Block V at Tarapur Unit 4. Again, it enhanced Xanthine capacity to 5,000 TPA in 2023.The RD centre in Nerul, Navi Mumbai became fully operational in FY 2024. The Company has commenced operations for its semicommercial block at the USFDA intermediate manufacturing site in Vapi in FY24. The Xanthine capacity was enhanced to 5000 TPA in 202324.

Aarti Pharmalabs reported a Q1 FY 2025-26 revenue of ₹386.19 crore, up 14.4% YoY, with net profit increased 25.6% to ₹51.3 crore. For the full year FY2025–2026, revenue reached ₹2125.19 crore and profit touched at ₹272.4 crore. As of Jun '25, Aarti Pharmalabs’s market capitalisation stood at ₹8,270.56 crores. Shareholding as of Jun '25 shows promoters holding 43.7%, with FIIs at 7.3%, DIIs at 7.9%, and public at 41.1%.

As of 17 Sep, 2025, Aarti Pharmalabs share price is ₹918.9. The stock opened at ₹917 and had closed at ₹912.4 the previous day. During today’s trading session, Aarti Pharmalabs share price moved between ₹912.95 and ₹921.55, with an average price for the day of ₹917.25. Over the last 52 weeks, the stock has recorded a low of ₹557.05 and a high of ₹971.00. In terms of performance, Aarti Pharmalabs share price has increased by 24.4% over the past six months and has increased by 24.86% over the last year.